AR075587A1 - Derivados de bifenilo para el tratamiento de hepatitis c - Google Patents
Derivados de bifenilo para el tratamiento de hepatitis cInfo
- Publication number
- AR075587A1 AR075587A1 ARP100100520A ARP100100520A AR075587A1 AR 075587 A1 AR075587 A1 AR 075587A1 AR P100100520 A ARP100100520 A AR P100100520A AR P100100520 A ARP100100520 A AR P100100520A AR 075587 A1 AR075587 A1 AR 075587A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hepatitis
- treatment
- bifenylate
- derivatives
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 235000019256 formaldehyde Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Procesos para su preparacion, composiciones farmacéuticas que los contienen y su uso en terapia. Los compuestos son utiles en el tratamiento del virus de la hepatitis C. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1), o una sal farmacéuticamente aceptable del mismo, en donde L representa un anillo heteroaromático de cinco miembros que contiene 1 a 3 heteroátomos que se seleccionan independientemente de O, S y N; R1 representa SO2, NSO2R7 o NSO2NR7R8; R2 representa un enlace. CH2, CH2CH2 o CH2O; R3 representa H, alquilo C1-4, CH2OH, CHOHCH3 o Ph; R4 representa H, alquilo C1-4 o CO2R9; R5 representa H o alquilo C1-4; R6 representa H, alquilo C1-2, halogeno u OCF3; R7 representa alquilo C1-4; y R8 y R9 independientemente representan H o alquilo C1-4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15446009P | 2009-02-23 | 2009-02-23 | |
| US25007309P | 2009-10-09 | 2009-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075587A1 true AR075587A1 (es) | 2011-04-20 |
Family
ID=42126093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100520A AR075587A1 (es) | 2009-02-23 | 2010-02-23 | Derivados de bifenilo para el tratamiento de hepatitis c |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100215618A1 (es) |
| AR (1) | AR075587A1 (es) |
| TW (1) | TW201036968A (es) |
| UY (1) | UY32462A (es) |
| WO (1) | WO2010094977A1 (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2567047T3 (es) * | 2008-12-23 | 2016-04-19 | Abbvie Inc. | Derivados de pirimidina anti-virales |
| SG172353A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2541571C2 (ru) * | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
| KR101727876B1 (ko) | 2009-05-13 | 2017-04-17 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2853531A3 (en) * | 2009-06-11 | 2015-08-12 | AbbVie Bahamas Ltd. | Antiviral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| IN2012DN00999A (es) | 2009-07-16 | 2015-04-10 | Vertex Pharma | |
| KR20120076343A (ko) | 2009-09-04 | 2012-07-09 | 글락소스미스클라인 엘엘씨 | 화합물 |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201136942A (en) | 2009-12-18 | 2011-11-01 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| CN102791687B (zh) * | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2011232331A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| CA2815537A1 (en) | 2010-10-26 | 2012-05-03 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
| CN103189371B (zh) | 2010-11-04 | 2015-04-01 | 施万生物制药研发Ip有限责任公司 | 丙型肝炎病毒抑制剂 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| KR20190075142A (ko) | 2011-09-16 | 2019-06-28 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
| PH12014500988A1 (en) * | 2011-11-03 | 2014-06-09 | Theravance Inc | Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl -4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013163270A1 (en) * | 2012-04-25 | 2013-10-31 | Theravance, Inc. | Hepatitis c virus inhibitors |
| EP2850075B1 (en) | 2012-04-25 | 2017-02-22 | Theravance Biopharma R&D IP, LLC | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
| US8883135B2 (en) | 2012-05-03 | 2014-11-11 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor |
| HUE047777T2 (hu) | 2013-01-31 | 2020-05-28 | Gilead Pharmasset Llc | Két vírusellenes vegyület kombinációs készítménye |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| GB201305376D0 (en) * | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN109640970B (zh) * | 2016-06-23 | 2023-05-23 | 马里兰大学巴尔的摩分校 | 选择性p38α特异性MAPK抑制剂 |
| CN108794454B (zh) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| CN107814789B8 (zh) * | 2017-11-27 | 2021-01-01 | 常州寅盛药业有限公司 | 一种达卡他韦起始原料的合成方法 |
| MX2021006731A (es) | 2018-12-07 | 2021-09-23 | Univ Maryland | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. |
| US11286260B2 (en) | 2020-05-18 | 2022-03-29 | Gen1E Lifesciences Inc. | P38α mitogen-activated protein kinase inhibitors |
| US11390581B2 (en) | 2020-10-29 | 2022-07-19 | Gen1E Lifesciences Inc. | Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate |
| CN117120422A (zh) | 2021-03-23 | 2023-11-24 | Gen1E生命科学公司 | 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂 |
| JP7725617B2 (ja) | 2021-05-21 | 2025-08-19 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
| JP7723119B2 (ja) | 2021-05-21 | 2025-08-13 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス感染症の治療のための四環系化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1940786E (pt) * | 2005-09-16 | 2010-10-04 | Arrow Therapeutics Ltd | Derivados de bifenilo e sua utilização no tratamento de hepatite c |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) * | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2010
- 2010-02-22 UY UY0001032462A patent/UY32462A/es not_active Application Discontinuation
- 2010-02-22 WO PCT/GB2010/050295 patent/WO2010094977A1/en not_active Ceased
- 2010-02-23 AR ARP100100520A patent/AR075587A1/es unknown
- 2010-02-23 US US12/710,647 patent/US20100215618A1/en not_active Abandoned
- 2010-02-23 TW TW099105197A patent/TW201036968A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY32462A (es) | 2010-09-30 |
| TW201036968A (en) | 2010-10-16 |
| WO2010094977A1 (en) | 2010-08-26 |
| US20100215618A1 (en) | 2010-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075587A1 (es) | Derivados de bifenilo para el tratamiento de hepatitis c | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| CR20110617A (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| UY38059A (es) | Heterociclos sustituidos como agentes antivirales | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| UY27781A1 (es) | Compuestos químicos. | |
| ECSP088871A (es) | Derivados de triazolopirazina | |
| AR074876A1 (es) | Derivados de indol-pirimidina para tratar cancer | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR078201A1 (es) | Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR069508A1 (es) | Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento | |
| UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
| AR067927A1 (es) | Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. | |
| AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
| PE20141527A1 (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos | |
| UY28688A1 (es) | Derivados de amida | |
| MX2018010177A (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida. | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| EA202092955A1 (ru) | Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |